77 related articles for article (PubMed ID: 26079547)
1. SMAD4 gene promoter mutations in patients with thyroid tumors.
Nikolic A; Ristanovic M; Zivaljevic V; Rankov AD; Radojkovic D; Paunovic I
Exp Mol Pathol; 2015 Aug; 99(1):100-3. PubMed ID: 26079547
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA miR-146b-5p regulates signal transduction of TGF-β by repressing SMAD4 in thyroid cancer.
Geraldo MV; Yamashita AS; Kimura ET
Oncogene; 2012 Apr; 31(15):1910-22. PubMed ID: 21874046
[TBL] [Abstract][Full Text] [Related]
3. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
4. Structural and functional analysis of SMAD4 gene promoter in malignant pancreatic and colorectal tissues: detection of two novel polymorphic nucleotide repeats.
Nikolic A; Kojic S; Knezevic S; Krivokapic Z; Ristanovic M; Radojkovic D
Cancer Epidemiol; 2011 Jun; 35(3):265-71. PubMed ID: 21036691
[TBL] [Abstract][Full Text] [Related]
5. Mononucleotide repeats in the SMAD4 gene promoter in colon carcinoma tissue of Croatian patients.
Nikolic A; Cacev T; Aralica G; Popovic Hadzija M; Kapitanovic S; Radojkovic D
Exp Mol Pathol; 2015 Apr; 98(2):133-5. PubMed ID: 25742737
[TBL] [Abstract][Full Text] [Related]
6. A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours.
Lazzereschi D; Nardi F; Turco A; Ottini L; D'Amico C; Mariani-Costantini R; Gulino A; Coppa A
Oncogene; 2005 Aug; 24(34):5344-54. PubMed ID: 15940269
[TBL] [Abstract][Full Text] [Related]
7. A novel human Smad4 mutation is involved in papillary thyroid carcinoma progression.
D'Inzeo S; Nicolussi A; Donini CF; Zani M; Mancini P; Nardi F; Coppa A
Endocr Relat Cancer; 2012 Feb; 19(1):39-55. PubMed ID: 22109972
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression.
Wang LH; Kim SH; Lee JH; Choi YL; Kim YC; Park TS; Hong YC; Wu CF; Shin YK
Clin Cancer Res; 2007 Jan; 13(1):102-10. PubMed ID: 17200344
[TBL] [Abstract][Full Text] [Related]
9. Activation of nicotinamide N-methyltransferase gene promoter by hepatocyte nuclear factor-1beta in human papillary thyroid cancer cells.
Xu J; Capezzone M; Xu X; Hershman JM
Mol Endocrinol; 2005 Feb; 19(2):527-39. PubMed ID: 15486044
[TBL] [Abstract][Full Text] [Related]
10. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
Wang D; Kanuma T; Mizunuma H; Takama F; Ibuki Y; Wake N; Mogi A; Shitara Y; Takenoshita S
Cancer Res; 2000 Aug; 60(16):4507-12. PubMed ID: 10969799
[TBL] [Abstract][Full Text] [Related]
11. Divergent mechanisms underlie Smad4-mediated positive regulation of the three genes encoding the basement membrane component laminin-332 (laminin-5).
Zboralski D; Böckmann M; Zapatka M; Hoppe S; Schöneck A; Hahn SA; Schmiegel W; Schwarte-Waldhoff I
BMC Cancer; 2008 Jul; 8():215. PubMed ID: 18664273
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors.
Máximo V; Soares P; Lima J; Cameselle-Teijeiro J; Sobrinho-Simões M
Am J Pathol; 2002 May; 160(5):1857-65. PubMed ID: 12000737
[TBL] [Abstract][Full Text] [Related]
13. Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario site of the breast cancer family registry (CFR).
Tram E; Ibrahim-Zada I; Briollais L; Knight JA; Andrulis IL; Ozcelik H
Breast Cancer Res; 2011 Aug; 13(4):R77. PubMed ID: 21835029
[TBL] [Abstract][Full Text] [Related]
14. Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis.
Imai Y; Kurokawa M; Izutsu K; Hangaishi A; Maki K; Ogawa S; Chiba S; Mitani K; Hirai H
Oncogene; 2001 Jan; 20(1):88-96. PubMed ID: 11244507
[TBL] [Abstract][Full Text] [Related]
15. Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.
Peng B; Fleming JB; Breslin T; Grau AM; Fojioka S; Abbruzzese JL; Evans DB; Ayers D; Wathen K; Wu T; Robertson KD; Chiao PJ
Clin Cancer Res; 2002 Nov; 8(11):3628-38. PubMed ID: 12429655
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
17. Somatic alterations in juvenile polyps from BMPR1A and SMAD4 mutation carriers.
Blatter RH; Plasilova M; Wenzel F; Gokaslan ST; Terracciano L; Ashfaq R; Heinimann K
Genes Chromosomes Cancer; 2015 Sep; 54(9):575-82. PubMed ID: 26171675
[TBL] [Abstract][Full Text] [Related]
18. The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors.
Ali S; Cohen C; Little JV; Sequeira JH; Mosunjac MB; Siddiqui MT
Diagn Cytopathol; 2007 Oct; 35(10):644-8. PubMed ID: 17854080
[TBL] [Abstract][Full Text] [Related]
19. SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.
Singh P; Srinivasan R; Wig JD
Pancreas; 2012 May; 41(4):541-6. PubMed ID: 22504380
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of SMAD4 by MZF1 inhibits migration of human gastric cancer cells.
Lee JH; Kim SS; Lee HS; Hong S; Rajasekaran N; Wang LH; Choi JS; Shin YK
Int J Oncol; 2017 Jan; 50(1):272-282. PubMed ID: 27922669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
